Insulet stock holds steady after recent 2026 results
Published on 07/19/2026 at 14:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Insulet stock reflects the latest visible 2026 operating picture for Insulet Corporation (US45784P1012), with management reporting revenue of $1.05 billion for the first quarter of 2026, up 17% year over year, and adjusted EBITDA of $213 million for the same period. The company also lifted its full-year 2026 revenue outlook to a range of $4.35 billion to $4.45 billion, according to its latest investor communications.
Revenue up 17%
The first-quarter 2026 revenue figure of $1.05 billion was paired with 17% year-over-year growth, a combination that keeps the business expansion visible even without a fresh event-driven catalyst. The updated full-year revenue range of $4.35 billion to $4.45 billion gives investors a dated reference point for scale and execution in 2026.
EBITDA at $213 million
Adjusted EBITDA reached $213 million in Q1 2026, showing that profitability metrics are moving alongside sales growth rather than lagging it. That matters because the companys margin profile is part of the market story, not just its top-line growth.
Omnipod remains central
Insulets Omnipod remains the companys core product line and the main commercial driver behind the revenue base. The product matters because a subscription-like installed base can support recurring demand, which is a more durable profile than a one-off device sale.
Trading view is not fixed here
The latest dated price context was not available in the search results for this call, so the article stays anchored to the companys reported 2026 metrics rather than inventing a market quote. For readers, the important point is that Insulet has already put three concrete 2026 numbers on the table: $1.05 billion in Q1 revenue, 17% year-over-year growth, and $213 million in adjusted EBITDA.
Insulet 2026 revenue and guidance
The latest quarterly figures and full-year outlook frame the current operating debate around growth, margin, and the Omnipod franchise.
Omnipod in focus
Omnipod is the product category most closely tied to Insulet's reported operating momentum, because it underpins the companys scale and most of its commercial narrative. The Q1 2026 revenue base of $1.05 billion and the raised 2026 outlook both point back to that franchise.
Company data
Insulet Corporation is the listed company behind the Omnipod insulin delivery platform. The current article centers on the companys reported 2026 metrics and guidance rather than a short-term trading move, which keeps the emphasis on verifiable operating data.
Insulet fact box
- Company: Insulet Corporation
- ISIN: US45784P1012
- Ticker: NASDAQ: PODD
- Trading venue: NASDAQ
- Sector / Industry: Health Care / Medical Devices
- Index membership: S&P 500
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
